上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
15期
73-75
,共3页
林楠%范松华%金慧%施海斌
林楠%範鬆華%金慧%施海斌
림남%범송화%금혜%시해빈
柳氮磺吡啶肠溶片%溶出曲线%?2 相似因子
柳氮磺吡啶腸溶片%溶齣麯線%?2 相似因子
류담광필정장용편%용출곡선%?2 상사인자
sulfasalazine enteric-coated tablets%dissolution profiles%?2 factor
目的:评价柳氮磺吡啶肠溶片新老工艺与市售产品体外溶出曲线的相似度。方法:转篮法测定溶出度,紫外分光光度法检测,采用?2相似因子法评价受试制剂和市售参比制剂溶出曲线的相似度。结果:pH 6.0条件下各个厂家柳氮磺吡啶肠溶片的溶出度均小于50。在溶出介质 pH 6.8与 pH 7.5磷酸盐缓冲液下,新工艺与市售制剂的相似因子为43、43,老工艺与市售制剂的相似因子为39、22。结论:新老工艺与市售制剂在3种不同介质下溶出曲线不相似,但是新工艺比老工艺有所改进,提示该试验药品处方需要继续优化。
目的:評價柳氮磺吡啶腸溶片新老工藝與市售產品體外溶齣麯線的相似度。方法:轉籃法測定溶齣度,紫外分光光度法檢測,採用?2相似因子法評價受試製劑和市售參比製劑溶齣麯線的相似度。結果:pH 6.0條件下各箇廠傢柳氮磺吡啶腸溶片的溶齣度均小于50。在溶齣介質 pH 6.8與 pH 7.5燐痠鹽緩遲液下,新工藝與市售製劑的相似因子為43、43,老工藝與市售製劑的相似因子為39、22。結論:新老工藝與市售製劑在3種不同介質下溶齣麯線不相似,但是新工藝比老工藝有所改進,提示該試驗藥品處方需要繼續優化。
목적:평개류담광필정장용편신로공예여시수산품체외용출곡선적상사도。방법:전람법측정용출도,자외분광광도법검측,채용?2상사인자법평개수시제제화시수삼비제제용출곡선적상사도。결과:pH 6.0조건하각개엄가류담광필정장용편적용출도균소우50。재용출개질 pH 6.8여 pH 7.5린산염완충액하,신공예여시수제제적상사인자위43、43,로공예여시수제제적상사인자위39、22。결론:신로공예여시수제제재3충불동개질하용출곡선불상사,단시신공예비로공예유소개진,제시해시험약품처방수요계속우화。
Objective: To evaluate the similarity of dissolution profiles of sulfasalazine enteric-coated tablets produced by old or new preparation process and a commercial ones. Methods: Dissolution was determined by rotating basket method and UV spectrophotometry and the dissolution similarity among those tablets was evaluated by the similarity factor approach. Results: The dissolution of all the products was less than 50% at pH 6.0. In the dissolution medium of pH 6.8 and pH 7.5 phosphate buffer solution, ?2 similarity factors of the tablets produced by new preparation process and the commercial product were 43 and 43 while they were 39 and 22 for the tables produced by old preparation process and the commercial ones. Conclusion: The dissolution profiles of the tables produced by new or old preparation process in 3 different media were not similar to those of commercial ones, but they were much better for the tablets produced by the new preparation process than the ones by the old process, suggesting that the preparation process for sulfasalazine enteric-coated tablets needs to be further optimized.